Clinical Trials Browser

Interventional × Neoplasms, Plasma Cell × imetelstat × Clear all

NCT00594126 2015-12-24

Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00718601 2015-12-24

Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell